Enrica Mezzalana, Ph.D.

Senior Consultant

Portrait-of-Enrica-Mezzalana_Pharmetheus

Bio

  • Joined Pharmetheus in 2019, actively working in client projects and with continuous improvements
  • Expertise includes pharmacometrics (especially time-to-event models and target-mediated drug disposition models) and physiological based pharmacokinetic modeling (PBPK, mainly for drug-drug interactions) in therapeutic areas such as oncology, pain, and diabetes
  • Previously worked as Modeling and Simulation Scientist at SGS Exprimo NV, Belgium, where she developed, interpreted, and reported population pharmacokinetic-pharmacodynamic models, optimal design, and physiological based pharmacokinetic modeling for drug-drug interaction predictions, as Clinical Pharmacology and Pharmacometrics Specialist at Menarini Ricerche, Italy, and as Postdoctoral Research Fellow at University of Pavia, Italy
  • M.Sc. in Bioengineering (2010) from the University of Padova, Italy, and Ph.D. in Bioengineering and Bioinformatics (2014) from University of Pavia, Italy
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Phase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEKTarget engagement analysis of belimumab in patients with systemic lupus erythematosus (SLE) and primary Sjogren’s syndrome (pSS)Imeglimin Population Pharmacokinetics and Dose Adjustment Predictions for Renal Impairment in Japanese and Western Patients with Type 2 DiabetesPopulation Pharmacokinetic Modelling and Simulation of Imeglimin in Type 2 Diabetes Patients to Support Dose Recommendations to Patients with Renal ImpairmentA Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and CaffeineA Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol and Caffeine